Ispire Technology Inc.

What they do

Ispire designs, markets, and distributes vaping hardware for nicotine (e-cigarettes) and cannabis (cartridges, disposables). Nicotine products are sold under the Aspire brand through distributors, while cannabis hardware is sold under the Ispire brand on an ODM basis to cannabis companies. The company does not handle cannabis plant material and is not subject to cannabis-specific tax rules like IRC 280E.

Revenue drivers

• Nicotine vaping products (Aspire brand) — Global e-cigarette sales, primarily through distributors; being expanded with new Ispire-branded products under licensing arrangements.
• Cannabis vaping hardware (Ispire brand) — ODM sales to multi-state operators, brand owners, and co-packers in the U.S., Canada, and South Africa.
• Malaysia manufacturing expansion — Newly licensed facility expected to produce nicotine vapor and pouch products, with a backlog of customer demand.

Recent performance

Fiscal 2025 revenue fell to $127.5M from $151.9M in 2024, with net loss widening to $39.2M from $14.8M. Quarterly revenue has been volatile: $20.1M (June 2025), $30.4M (Sept 2025), $20.3M (Dec 2025), $18.7M (March 2026). As of March 2026, the company had $18.0M cash, $92.1M liabilities, and negative shareholders' equity of $16.2M.

Strategy

Management is transitioning manufacturing to Malaysia to reduce geopolitical risk and costs, aiming for comparable production costs to China. They are focusing on higher-quality customers, especially larger MSOs, to reduce accounts receivable and improve margins. The company is also pursuing FDA approvals for age-gating technology via a joint venture (IKE Tech) and launching new products like Sprout with Raw Garden.

Risks

• Sustained losses — Net losses have grown from $1.9M in 2022 to $39.2M in 2025, with no assurance of future profitability.
• Negative equity and liquidity — Shareholders' equity was -$16.2M as of March 2026, with total liabilities exceeding assets by $16.2M.
• Regulatory and compliance — New Chinese export VAT rebate cancellation and FDA PMTA requirements on Chinese exporters could impact supply chain and costs.
• Dependence on third-party manufacturer — The company relies on Shenzhen Yi Jia Technology for supply, and any disruption could hurt operations.

Outlook

Management expects to begin nicotine vapor production in Malaysia by end of June 2026, with a backlog of orders. They anticipate cost improvements as Malaysia scales, supported by China's VAT rebate cancellation which improves Malaysia's competitive position. However, revenue has declined in recent quarters and the company continues to face regulatory and financial uncertainties.